1
|
Kim JH, Kim HK, Lee SW, Son YD, Kim JH. The Relationship between Character Traits and In Vivo Cerebral Serotonin Transporter Availability in Healthy Subjects: A High-Resolution PET Study with C-11 DASB. Pharmaceuticals (Basel) 2023; 16:ph16050759. [PMID: 37242542 DOI: 10.3390/ph16050759] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2023] [Revised: 05/14/2023] [Accepted: 05/16/2023] [Indexed: 05/28/2023] Open
Abstract
To elucidate the potential roles of serotonergic activity in human character traits (i.e., self-directedness, cooperativeness, and self-transcendence), we investigated the relationship between these character traits and serotonin transporter (5-HTT) in healthy subjects. Twenty-four participants underwent High-Resolution Research Tomograph-positron emission tomography scans with [11C]DASB. To quantify 5-HTT availability, binding potential (BPND) of [11C]DASB was obtained using the simplified reference tissue model. The Temperament and Character Inventory was used to assess subjects' levels of three character traits. There were no significant correlations between the three character traits. Self-directedness was significantly positively correlated with [11C]DASB BPND in the left hippocampus, left middle occipital gyrus, bilateral superior parietal gyrus, left inferior parietal gyrus, left middle temporal gyrus (MTG), and left inferior temporal gyrus (ITG). Cooperativeness was significantly negatively correlated with [11C]DASB BPND in the median raphe nucleus. Self-transcendence was significantly negatively correlated with [11C]DASB BPND in the right MTG and right ITG. Our results show significant correlations between the three character traits and 5-HTT availability in specific brain regions. In particular, self-directedness was significantly positively correlated with 5-HTT availability, suggesting that a goal-oriented, self-confident, and resourceful character may be related to higher serotonergic neurotransmission.
Collapse
Affiliation(s)
- Jeong-Hee Kim
- Biomedical Engineering Research Center, Gachon University, Incheon 21936, Republic of Korea
- Department of Biomedical Engineering, College of IT Convergence, Gachon University, Seongnam-si 13120, Republic of Korea
| | - Hang-Keun Kim
- Biomedical Engineering Research Center, Gachon University, Incheon 21936, Republic of Korea
- Department of Biomedical Engineering, College of IT Convergence, Gachon University, Seongnam-si 13120, Republic of Korea
- Neuroscience Research Institute, Gachon University, Incheon 21565, Republic of Korea
| | - Sang-Wha Lee
- Department of Chemical and Biological Engineering, Gachon University, Seongnam-si 13120, Republic of Korea
| | - Young-Don Son
- Biomedical Engineering Research Center, Gachon University, Incheon 21936, Republic of Korea
- Department of Biomedical Engineering, College of IT Convergence, Gachon University, Seongnam-si 13120, Republic of Korea
- Neuroscience Research Institute, Gachon University, Incheon 21565, Republic of Korea
| | - Jong-Hoon Kim
- Neuroscience Research Institute, Gachon University, Incheon 21565, Republic of Korea
- Department of Psychiatry, Gachon University College of Medicine, Gil Medical Center, Gachon University, Incheon 21565, Republic of Korea
| |
Collapse
|
2
|
Yang T, Lam RW, Huang J, Su Y, Liu J, Yang X, Yang L, Zhu N, Zhao G, Mao R, Zhou R, Xia W, Liu H, Wang Z, Chen J, Fang Y. Exploring the Effects of Temperament on Gray Matter Volume of Frontal Cortex in Patients with Mood Disorders. Neuropsychiatr Dis Treat 2021; 17:183-193. [PMID: 33519204 PMCID: PMC7837575 DOI: 10.2147/ndt.s287351] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/17/2020] [Accepted: 12/14/2020] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND Patients with bipolar disorder (BD) and patients with major depressive disorder (MDD) have relatively specific temperament and structural abnormalities of brain regions related to emotion and cognition. However, the effects of temperament factors on the structure of frontal and temporal cortex is still unclear. The aims of this study were to explore the differences and relationships between temperament characteristics and the gray matter volume of frontal and temporal cortex in patients with BD or MDD. METHODS T1-weighted magnetic resonance imaging (MRI) data, demographic and clinical information were obtained from 279 depressed patients (90 patients with BD, 189 patients with MDD) and 162 healthy controls (HC). Temperament was assessed with the Chinese short version of Temperament Evaluation of Memphis, Pisa and San Diego - Auto questionnaire (TEMPS-A). The Desikan-Killiany atlas was used for yielding gray matter volume by FreeSurfer 6.0 software suite. A total of 22 frontal and temporal regions were chosen as regions of interest (ROIs). RESULTS Compared with patients with MDD, patients with BD had higher TEMPS-A total scores and scores on cyclothymic, irritable and hyperthymic subscales. The gray matter volume in bilateral rostral middle frontal gyrus (RMFG), left temporal pole and right superior frontal gyrus were reduced in patients with BD. Patients with MDD only had lower gray matter volume in bilateral temporal pole. In the pooled patients, there were negative associations between hyperthymia and gray matter volume in right RMFG. CONCLUSION Patients with BD and MDD had different temperament characteristics. The prominent temperament subscales in patients with BD were cyclothymia, irritable and hyperthymia. Patients with greater hyperthymia had lower gray matter volume in right frontal gyrus. Temperament may reflect an endophenotype in patients with mood disorders, especially in BD.
Collapse
Affiliation(s)
- Tao Yang
- Clinical Research Center & Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.,Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada
| | - Raymond W Lam
- Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada
| | - Jia Huang
- Clinical Research Center & Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China
| | - Yousong Su
- Clinical Research Center & Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China
| | - Jing Liu
- Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada
| | - Xiaorui Yang
- Clinical Research Center & Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China
| | - Lu Yang
- Clinical Research Center & Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China
| | - Na Zhu
- Shanghai Pudong New Area Mental Health Center, Tongji University School of Medicine, Shanghai, People's Republic of China
| | - Guoqing Zhao
- Department of Psychology, Provincial Hospital Affiliated to Shandong University, Jinan, People's Republic of China
| | - Ruizhi Mao
- Clinical Research Center & Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China
| | - Rubai Zhou
- Clinical Research Center & Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China
| | - Weiping Xia
- Department of Medical Psychology, Xinhua Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, People's Republic of China
| | - Hongmei Liu
- Clinical Research Center & Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China
| | - Zuowei Wang
- Division of Mood Disorders, Shanghai Hongkou District Mental Health Center, Shanghai, People's Republic of China
| | - Jun Chen
- Clinical Research Center & Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China
| | - Yiru Fang
- Clinical Research Center & Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.,CAS Center for Excellence in Brain Science and Intelligence Technology, Shanghai, People's Republic of China.,Shanghai Key Laboratory of Psychotic Disorders, Shanghai, People's Republic of China
| |
Collapse
|
3
|
Turtonen O, Saarinen A, Nummenmaa L, Tuominen L, Tikka M, Armio RL, Hautamäki A, Laurikainen H, Raitakari O, Keltikangas-Järvinen L, Hietala J. Adult Attachment System Links With Brain Mu Opioid Receptor Availability In Vivo. Biol Psychiatry Cogn Neurosci Neuroimaging 2020; 6:360-369. [PMID: 33431346 DOI: 10.1016/j.bpsc.2020.10.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/07/2020] [Revised: 10/05/2020] [Accepted: 10/22/2020] [Indexed: 10/23/2022]
Abstract
BACKGROUND Secure attachment is important in maintaining an individual's health and well-being. Attachment disturbances increase the risk for developing psychiatric disorders such as affective disorders. Yet, the neurobiological correlates of human attachment are poorly understood at the neurotransmitter level. We investigated whether adult attachment style is linked to functioning of the opioid and serotonergic systems in the human brain. METHODS We used positron emission tomography with radioligands [11C]carfentanil and [11C]MADAM to quantify mu opioid receptor (n = 39) and serotonin transporter (n = 37) availability in volunteers with no current psychiatric disorders. Attachment style was determined according to the Dynamic-Maturational Model of Attachment and Adaptation with the structured Adult Attachment Interview. RESULTS Secure attachment was associated with higher mu opioid receptor availability in the hippocampus, amygdala, thalamus, and prefrontal cortex when compared with insecure (i.e., avoidant or ambivalent groups combined) attachment. In contrast, attachment style was not associated with serotonin transporter availability. CONCLUSIONS Our results provide preliminary in vivo evidence that the opioid system may be involved in the neurocircuits associated with individual differences in adult attachment behavior. The results suggest that variation in mu opioid receptor availability may be linked with the individuals' social relationships and psychosocial well-being and thus contributes to risk for psychiatric morbidity.
Collapse
Affiliation(s)
- Otto Turtonen
- Turku PET Centre, Turku University Hospital and University of Turku, Turku, Finland
| | - Aino Saarinen
- Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Research Unit of Psychology, University of Oulu, Oulu, Finland
| | - Lauri Nummenmaa
- Turku PET Centre, Turku University Hospital and University of Turku, Turku, Finland; Department of Psychology, University of Turku, Turku, Finland
| | - Lauri Tuominen
- Turku PET Centre, Turku University Hospital and University of Turku, Turku, Finland; Department of Psychiatry, Turku University Hospital and University of Turku, Turku, Finland; Institute of Mental Health Research, Royal Ottawa Mental Health Centre, Ottawa, Ontario, Canada
| | - Maria Tikka
- Department of Psychiatry, Turku University Hospital and University of Turku, Turku, Finland
| | - Reetta-Liina Armio
- Turku PET Centre, Turku University Hospital and University of Turku, Turku, Finland; Department of Psychiatry, Turku University Hospital and University of Turku, Turku, Finland
| | - Airi Hautamäki
- Swedish School of Social Science, University of Helsinki, Helsinki, Finland
| | - Heikki Laurikainen
- Turku PET Centre, Turku University Hospital and University of Turku, Turku, Finland; Department of Psychiatry, Turku University Hospital and University of Turku, Turku, Finland
| | - Olli Raitakari
- Research Centre of Applied and Preventive Cardiovascular Medicine, Faculty of Medicine, University of Turku, Turku, Finland; Centre for Population Health Research, University of Turku and Turku University Hospital, Turku, Finland; Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland
| | | | - Jarmo Hietala
- Turku PET Centre, Turku University Hospital and University of Turku, Turku, Finland; Department of Psychiatry, Turku University Hospital and University of Turku, Turku, Finland.
| |
Collapse
|
4
|
Shao X, Zhu G. Associations Among Monoamine Neurotransmitter Pathways, Personality Traits, and Major Depressive Disorder. Front Psychiatry 2020; 11:381. [PMID: 32477180 PMCID: PMC7237722 DOI: 10.3389/fpsyt.2020.00381] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/19/2020] [Accepted: 04/16/2020] [Indexed: 12/13/2022] Open
Abstract
Major depressive disorder (MDD) is a complex psychiatric disease requiring multidisciplinary approaches to identify specific risk factors and establish more efficacious treatment strategies. Although the etiology and pathophysiology of MDD are not clear until these days, it is acknowledged that they are almost certainly multifactorial and comprehensive. Monoamine neurotransmitter system dysfunction and specific personality traits are independent risk factors for depression and suicide. These factors also demonstrate complex interactions that influence MDD pathogenesis and symptom expression. In this review, we assess these relationships with the aim of providing a reference for the development of precision medicine.
Collapse
Affiliation(s)
- Xiaojun Shao
- Department of Psychiatry, The First Affiliated Hospital of China Medical University, Shenyang, China
| | - Gang Zhu
- Department of Psychiatry, The First Affiliated Hospital of China Medical University, Shenyang, China.,Central Laboratory, The First Affiliated Hospital of China Medical University, Shenyang, China
| |
Collapse
|
5
|
Lozupone M, La Montagna M, D'Urso F, Daniele A, Greco A, Seripa D, Logroscino G, Bellomo A, Panza F. The Role of Biomarkers in Psychiatry. Adv Exp Med Biol 2019; 1118:135-162. [PMID: 30747421 DOI: 10.1007/978-3-030-05542-4_7] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Psychiatric illnesses are cognitive and behavioral disorders of the brain. At present, psychiatric diagnosis is based on DSM-5 criteria. Even if endophenotype specificity for psychiatric disorders is discussed, it is difficult to study and identify psychiatric biomarkers to support diagnosis, prognosis, or clinical response to treatment. This chapter investigates the innovative biomarkers of psychiatric diseases for diagnosis and personalized treatment, in particular post-genomic data and proteomic analyses.
Collapse
Affiliation(s)
- Madia Lozupone
- Neurodegenerative Disease Unit, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy
| | - Maddalena La Montagna
- Psychiatric Unit, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy
| | - Francesca D'Urso
- Psychiatric Unit, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy
| | - Antonio Daniele
- Institute of Neurology, Catholic University of Sacred Heart, Rome, Italy.,Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - Antonio Greco
- Geriatric Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, Foggia, Italy
| | - Davide Seripa
- Geriatric Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, Foggia, Italy
| | - Giancarlo Logroscino
- Neurodegenerative Disease Unit, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy.,Department of Clinical Research in Neurology, University of Bari Aldo Moro, Lecce, Italy
| | - Antonello Bellomo
- Psychiatric Unit, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy
| | - Francesco Panza
- Neurodegenerative Disease Unit, Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy. .,Geriatric Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, Foggia, Italy. .,Department of Clinical Research in Neurology, University of Bari Aldo Moro, Lecce, Italy.
| |
Collapse
|
6
|
Kim JH, Choe YS, Cumming P, Son YD, Kim HK, Joo YH, Kim JH. Relationship of self-transcendence traits with in vivo dopamine D2/3 receptor availability and functional connectivity: An [ 18 F]fallypride PET and fMRI study. Synapse 2019; 73:e22121. [PMID: 31206840 DOI: 10.1002/syn.22121] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2019] [Revised: 05/30/2019] [Accepted: 06/08/2019] [Indexed: 12/13/2022]
Abstract
Genetic research has implicated dopamine neurotransmission in the expression of the self-transcendence trait in humans. However, molecular imaging of dopaminergic markers is undocumented in relation to this personality trait. In this multimodal imaging study, we first investigated the relationship between the self-transcendence trait and in vivo dopamine D2/3 receptor availability using [18 F]fallypride positron emission tomography (PET). We next conducted seed-based functional connectivity analyses using resting-state functional magnetic resonance imaging (rs-fMRI) data with regions derived from the PET analysis as seeds to explore the functional significance of D2/3 receptor availability foci associated with the self-transcendence trait. Twenty-one healthy subjects underwent high-resolution PET with [18 F]fallypride and a subset of 18 subjects also completed 3-Tesla rs-fMRI. The Temperament and Character Inventory was used to measure the self-transcendence trait. A voxel-based whole brain analysis revealed that the [18 F]fallypride binding potential (BPND ) within the cluster of the left insula was significantly positively correlated with self-transcendence trait scores. A region-of-interest analysis also showed a significant positive correlation between self-transcendence and [18 F]fallypride BPND in the left insula. The exploratory [18 F]fallypride BPND seed-based rs-fMRI analysis showed that the functional connectivity from the left insula seed to the prefrontal cortices (including the inferior frontal region) was negatively associated with self-transcendence trait scores. The results of the present study suggest that D2/3 receptor-mediated neurotransmission in the left insula may constitute a significant neurobiological factor in the self-transcendence trait. The negative associations between BPND seed-based functional connectivity and self-transcendence trait scores may suggest reduced prefrontal control in this personality trait.
Collapse
Affiliation(s)
- Jeong-Hee Kim
- Research Institute for Advanced Industrial Technology, Korea University, Sejong, South Korea.,Neuroscience Research Institute, Gachon University, Incheon, South Korea
| | - Yi-Seul Choe
- Neuroscience Research Institute, Gachon University, Incheon, South Korea
| | - Paul Cumming
- Department of Nuclear Medicine, Inselspital, Bern University, Bern, Switzerland.,School of Psychology and Counselling and IHBI, Queensland University of Technology, Brisbane, Queensland, Australia
| | - Young-Don Son
- Neuroscience Research Institute, Gachon University, Incheon, South Korea.,Department of Biomedical Engineering, College of Health Science, Gachon University, Incheon, South Korea
| | - Hang-Keun Kim
- Neuroscience Research Institute, Gachon University, Incheon, South Korea.,Department of Biomedical Engineering, College of Health Science, Gachon University, Incheon, South Korea
| | - Yo-Han Joo
- Neuroscience Research Institute, Gachon University, Incheon, South Korea
| | - Jong-Hoon Kim
- Neuroscience Research Institute, Gachon University, Incheon, South Korea.,Department of Psychiatry, Gachon University College of Medicine, Gil Medical Center, Gachon University, Incheon, South Korea
| |
Collapse
|
7
|
Stenbaek DS, Kristiansen S, Burmester D, Madsen MK, Frokjaer VG, Knudsen GM, Fisher PM. Trait Openness and serotonin 2A receptors in healthy volunteers: A positron emission tomography study. Hum Brain Mapp 2019; 40:2117-2124. [PMID: 30633430 DOI: 10.1002/hbm.24511] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2018] [Revised: 12/13/2018] [Accepted: 12/28/2018] [Indexed: 12/21/2022] Open
Abstract
Recent research found lasting increases in personality trait Openness in healthy individuals and patients after administration of the serotonin 2A receptor (5-HT2A R) agonist psilocybin. However, no studies have investigated whether 5-HT2A R availability as imaged using positron emission tomography (PET) is associated with this trait. In 159 healthy individuals (53 females), the association between 5-HT2A R binding in neocortex imaged with [18 F]altanserin or [11 C]Cimbi-36 PET and personality trait Openness was investigated using linear regression models. In these models the influence of sex on the association was also investigated. Trait Openness was assessed with the NEO Personality Inventory-Revised. No significant associations between neocortical 5-HT2A R binding and trait Openness were found for [18 F]altanserin (p = 0.5) or [11 C]Cimbi-36 (p = 0.8). Pooling the data in a combined model did not substantially change our results (p = 0.4). No significant interactions with sex were found (p > 0.35). Our results indicate that differences in 5-HT2A R availability are not related to variations in trait Openness in healthy individuals. Although stimulation of the 5-HT2A R with compounds such as psilocybin may contribute to long-term changes in trait Openness, there is no evidence in favor of an association between 5-HT2A R and trait Openness.
Collapse
Affiliation(s)
- Dea Siggaard Stenbaek
- Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark.,Center for Integrated Molecular Brain Imaging, Rigshospitalet, Copenhagen, Denmark.,The Neuroscience Centre, Rigshospitalet, Copenhagen, Denmark
| | - Sara Kristiansen
- Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark.,Center for Integrated Molecular Brain Imaging, Rigshospitalet, Copenhagen, Denmark.,The Neuroscience Centre, Rigshospitalet, Copenhagen, Denmark
| | - Daniel Burmester
- Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark.,Center for Integrated Molecular Brain Imaging, Rigshospitalet, Copenhagen, Denmark.,The Neuroscience Centre, Rigshospitalet, Copenhagen, Denmark
| | - Martin Korsbak Madsen
- Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark.,Center for Integrated Molecular Brain Imaging, Rigshospitalet, Copenhagen, Denmark.,The Neuroscience Centre, Rigshospitalet, Copenhagen, Denmark
| | - Vibe Gedsoe Frokjaer
- Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark.,Center for Integrated Molecular Brain Imaging, Rigshospitalet, Copenhagen, Denmark.,The Neuroscience Centre, Rigshospitalet, Copenhagen, Denmark
| | - Gitte Moos Knudsen
- Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark.,Center for Integrated Molecular Brain Imaging, Rigshospitalet, Copenhagen, Denmark.,The Neuroscience Centre, Rigshospitalet, Copenhagen, Denmark
| | - Patrick MacDonald Fisher
- Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark.,Center for Integrated Molecular Brain Imaging, Rigshospitalet, Copenhagen, Denmark.,The Neuroscience Centre, Rigshospitalet, Copenhagen, Denmark
| |
Collapse
|
8
|
Prillwitz CC, Rüber T, Reuter M, Montag C, Weber B, Elger CE, Markett S. The salience network and human personality: Integrity of white matter tracts within anterior and posterior salience network relates to the self-directedness character trait. Brain Res 2018; 1692:66-73. [DOI: 10.1016/j.brainres.2018.04.035] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2018] [Revised: 04/25/2018] [Accepted: 04/27/2018] [Indexed: 01/26/2023]
|
9
|
Porcelli S, Marsano A, Caletti E, Sala M, Abbiati V, Bellani M, Perlini C, Rossetti MG, Mandolini GM, Pigoni A, Paoli RA, Piccin S, Lazzaretti M, Fabbro D, Damante G, Bonivento C, Ferrari C, Rossi R, Pedrini L, Serretti A, Brambilla P. Temperament and Character Inventory in Bipolar Disorder versus Healthy Controls and Modulatory Effects of 3 Key Functional Gene Variants. Neuropsychobiology 2018; 76:209-221. [PMID: 30041166 DOI: 10.1159/000490955] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/20/2018] [Accepted: 06/18/2018] [Indexed: 12/11/2022]
Abstract
BACKGROUND Bipolar disorder (BD) has been associated with temperamental and personality traits, although the relationship is still to be fully elucidated. Several studies investigated the genetic basis of temperament and character, identifying catechol-O-methyltransferase (COMT), brain derived neurotrophic factor (BDNF), and serotonin transporter (5-HTT) gene variants as strong candidates. METHODS In the GECO-BIP study, 125 BD patients and 173 HC were recruited. Subjects underwent to a detailed assessment and the temperament and character inventory 125 items (TCI) was administrated. Three functional genetic variants within key candidate genes (COMT rs4680, BDNF rs6265, and the serotonin-transporter-linked polymorphic region (5-HTTLPR)) were genotyped. Univariate and multivariate analyses were performed. RESULTS Compared to HC, BD patients showed higher scores in novelty seeking (NS; p = 0.001), harm avoidance (HA; p < 0.001), and self transcendence (St; p < 0.001), and lower scores in self directness (p < 0.001) and cooperativeness (p < 0.001) TCI dimensions. Concerning the genetic analyses, COMT rs4680 was associated with NS in the total sample (p = 0.007) and in the male subsample (p = 0.022). When performing the analysis in the HC and BD samples, the association was confirmed only in HC (p = 0.012), and in the HC male subgroup in particular (p = 0.004). BDNF rs6265 was associated with St in the BD group (p = 0.017). CONCLUSION COMT rs4680 may modulate NS in males in the general population. This effect was not detected in BD patients, probably because BD alters the neurobiological basis of some TCI dimensions. BDNF rs6265 seems to modulate St TCI dimension only in BD patients, possibly modulating the previously reported association between rs6265 and BD treatment response. Further studies are needed to confirm our findings.
Collapse
Affiliation(s)
- Stefano Porcelli
- Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy
| | - Agnese Marsano
- Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy
| | - Elisabetta Caletti
- Department of Neurosciences and Mental Health, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
| | - Michela Sala
- Department of Mental Health, Azienda Sanitaria Locale Alessandria, Alessandria, Italy
| | - Vera Abbiati
- Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
| | - Marcella Bellani
- Department of Neurosciences, Biomedicine and Movement Sciences, Section of Psychiatry and Clinical Psychology, University of Verona, Verona, Italy.,UOC Psychiatry, Azienda Ospedaliera Universitaria Integrata Verona (AOUI), Verona, Italy
| | - Cinzia Perlini
- Department of Neurosciences, Biomedicine and Movement Sciences, Section of Psychiatry and Clinical Psychology, University of Verona, Verona, Italy.,UOC Psychiatry, Azienda Ospedaliera Universitaria Integrata Verona (AOUI), Verona, Italy
| | - Maria Gloria Rossetti
- Department of Neurosciences, Biomedicine and Movement Sciences, Section of Psychiatry and Clinical Psychology, University of Verona, Verona, Italy
| | - Gian Mario Mandolini
- Department of Neurosciences and Mental Health, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
| | - Alessandro Pigoni
- Department of Neurosciences and Mental Health, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
| | - Riccardo Augusto Paoli
- Department of Neurosciences and Mental Health, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
| | - Sara Piccin
- Scientific Institute IRCCS "Eugenio Medea," Polo FVG, San Vito al Tagliamento, Pordenone, Italy
| | - Matteo Lazzaretti
- Department of Neurosciences and Mental Health, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
| | - Dora Fabbro
- Institute of Medical Genetics, Department of Laboratory Medicine, University of Udine, Udine, Italy
| | - Giuseppe Damante
- Institute of Medical Genetics, Department of Laboratory Medicine, University of Udine, Udine, Italy
| | - Carolina Bonivento
- Unit of Psychiatry, Department of Medicine (DAME), University of Udine, Udine, Italy
| | - Clarissa Ferrari
- Service of Statistics, IRCCS Centro San Giovanni di Dio FBF, Brescia, Italy
| | - Roberta Rossi
- Unit of Psychiatry, IRCCS Centro San Giovanni di Dio FBF, Brescia, Italy
| | - Laura Pedrini
- Unit of Psychiatry, IRCCS Centro San Giovanni di Dio FBF, Brescia, Italy
| | - Alessandro Serretti
- Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy
| | - Paolo Brambilla
- Department of Neurosciences and Mental Health, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.,Department of Psychiatry and Behavioral Sciences, University of Texas at Houston, Houston, Texas, USA
| | | |
Collapse
|
10
|
Farde L, Plavén-Sigray P, Borg J, Cervenka S. Brain neuroreceptor density and personality traits: towards dimensional biomarkers for psychiatric disorders. Philos Trans R Soc Lond B Biol Sci 2018; 373:20170156. [PMID: 29483342 PMCID: PMC5832682 DOI: 10.1098/rstb.2017.0156] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/23/2017] [Indexed: 02/06/2023] Open
Abstract
Positron emission tomography has, for 30 years, been used in numerous case-control studies searching for hypothesized differences in the density of neuroreceptor or transporter proteins in psychiatric disorders such as schizophrenia and depression. In most cases, the results have not been conclusive. One reason could be the sizeable interindividual variability in biochemical markers, which in twin studies have shown to emanate from both environmental and genetic factors, leading to low statistical power for the detection of group effects. On the other hand, the same interindividual variability has served as an opportunity for correlative studies on the biological underpinning of behaviour. Using this approach, a series of studies has linked markers for the dopamine and serotonin system to personality traits associated with psychiatric conditions. Based on increasing evidence for the view that many psychopathological states represent extremes of a continuum rather than distinct categories, this research strategy may lead to new biological insights about the vulnerability to and pathophysiology of major psychiatric disorders.This article is part of the theme issue 'Diverse perspectives on diversity: multi-disciplinary approaches to taxonomies of individual differences'.
Collapse
Affiliation(s)
- Lars Farde
- Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, 17176 Stockholm, Sweden
- Precision Medicine and Genomics, AstraZeneca, PET Science Centre, Karolinska Institutet, 17176 Stockholm, Sweden
| | - Pontus Plavén-Sigray
- Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, 17176 Stockholm, Sweden
| | - Jacqueline Borg
- Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, 17176 Stockholm, Sweden
| | - Simon Cervenka
- Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, 17176 Stockholm, Sweden
| |
Collapse
|
11
|
Stenbæk DS, Dam VH, Fisher PM, Hansen N, Hjordt LV, Frokjaer VG. No evidence for a role of the serotonin 4 receptor in five-factor personality traits: A positron emission tomography brain study. PLoS One 2017; 12:e0184403. [PMID: 28880910 PMCID: PMC5589219 DOI: 10.1371/journal.pone.0184403] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2017] [Accepted: 08/23/2017] [Indexed: 01/19/2023] Open
Abstract
Serotonin (5-HT) brain architecture appears to be implicated in normal personality traits as supported by genetic associations and studies using molecular brain imaging. However, so far, no studies have addressed potential contributions to variation in normal personality traits from in vivo serotonin 4 receptor (5-HT4R) brain availability, which has recently become possible to image with Positron Emission Tomography (PET). This is particularly relevant since availability of 5-HT4R has been shown to adapt to synaptic levels of 5-HT and thus offers information about serotonergic tone in the healthy brain. In 69 healthy participants (18 females), the associations between personality traits assessed with the five-factor NEO Personality Inventory-Revised (NEO PI-R) and regional cerebral 5-HT4R binding in neocortex, amygdala, hippocampus, and anterior cingulate cortex (ACC) were investigated using linear regression models. The associations between each of the five personality traits and a latent variable construct of global 5-HT4R levels were also evaluated using latent variable structural equation models. We found no significant associations between the five NEO personality traits and regional 5-HT4R binding (all p-values > .17) or the latent construct of global 5-HT4R levels (all p-values > .37). Our findings indicate that NEO personality traits and 5-HT4R are not related in healthy participants. Under the assumption that global 5-HT4R levels index 5-HT tone, our data also suggest that 5-HT tone per se is not directly implicated in normal personality traits.
Collapse
Affiliation(s)
- Dea Siggaard Stenbæk
- Neurobiology Research Unit, the Neuroscience Centre, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
- Center for Integrated Molecular Brain Imaging and Center for Experimental Medicine Neuropharmacology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
- * E-mail:
| | - Vibeke Høyrup Dam
- Neurobiology Research Unit, the Neuroscience Centre, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
- Center for Integrated Molecular Brain Imaging and Center for Experimental Medicine Neuropharmacology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
| | - Patrick MacDonald Fisher
- Neurobiology Research Unit, the Neuroscience Centre, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
- Center for Integrated Molecular Brain Imaging and Center for Experimental Medicine Neuropharmacology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
| | - Nanna Hansen
- Neurobiology Research Unit, the Neuroscience Centre, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
| | - Liv Vadskjær Hjordt
- Neurobiology Research Unit, the Neuroscience Centre, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
- Center for Integrated Molecular Brain Imaging and Center for Experimental Medicine Neuropharmacology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
- Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Vibe Gedsoe Frokjaer
- Neurobiology Research Unit, the Neuroscience Centre, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
- Center for Integrated Molecular Brain Imaging and Center for Experimental Medicine Neuropharmacology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
| |
Collapse
|
12
|
Tuominen L, Miettunen J, Cannon DM, Drevets WC, Frokjaer VG, Hirvonen J, Ichise M, Jensen PS, Keltikangas-Järvinen L, Klaver JM, Knudsen GM, Takano A, Suhara T, Hietala J. Neuroticism Associates with Cerebral in Vivo Serotonin Transporter Binding Differently in Males and Females. Int J Neuropsychopharmacol 2017; 20:963-970. [PMID: 29020405 PMCID: PMC5716061 DOI: 10.1093/ijnp/pyx071] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/10/2017] [Accepted: 08/03/2017] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND Neuroticism is a major risk factor for affective disorders. This personality trait has been hypothesized to associate with synaptic availability of the serotonin transporter, which critically controls serotonergic tone in the brain. However, earlier studies linking neuroticism and serotonin transporter have failed to produce converging findings. Because sex affects both the serotonergic system and the risk that neuroticism poses to the individual, sex may modify the association between neuroticism and serotonin transporter, but this question has not been investigated by previous studies. METHODS Here, we combined data from 4 different positron emission tomography imaging centers to address whether neuroticism is related to serotonin transporter binding in vivo. The data set included serotonin transporter binding potential values from the thalamus and striatum and personality scores from 91 healthy males and 56 healthy females. We specifically tested if the association between neuroticism and serotonin transporter is different in females and males. RESULTS We found that neuroticism and thalamic serotonin transporter binding potentials were associated in both males and females, but with opposite directionality. Higher neuroticism associated with higher serotonin transporter binding potential in males (standardized beta 0.292, P=.008), whereas in females, higher neuroticism associated with lower serotonin transporter binding potential (standardized beta -0.288, P=.014). CONCLUSIONS The finding is in agreement with recent studies showing that the serotonergic system is involved in affective disorders differently in males and females and suggests that contribution of thalamic serotonin transporter to the risk of affective disorders depends on sex.
Collapse
Affiliation(s)
- Lauri Tuominen
- Turku PET Centre, Turku University Hospital, Turku, Finland (Drs Tuominen, Hirvonen, and Hietala); Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA (Dr Tuominen); Center for Life Course Health Research, University of Oulu, Finland & Medical Research Center (MRC) Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland (Dr Miettunen); Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland, Galway, Ireland (Dr Cannon); Janssen Research & Development, LLC, of Johnson & Johnson, Titusville, NJ (Dr Drevets); Neurobiology Research Unit, Rigshospitalet, Denmark (Dr Knudsen); Center for Integrated Molecular Brain Imaging, Rigshospitalet, Denmark (Dr Frokjaer and Mr Jensen); Department of Radiology, University of Turku, Turku, Finland (Dr Hirvonen); Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institute for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Ichise, Takano, and Suhara); IBS, Unit of Personality, Work and Health Psychology, University of Helsinki, Helsinki, Finland (Dr Keltikangas-Järvinen); Department of Psychology, Southern Illinois University, Carbondale, Illinois (Dr Klaver); Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (Dr Knudsen); Center for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Dr Takano); Department of Psychiatry, University of Turku, Turku, Finland (Dr Hietala),Correspondence: Lauri Tuominen, MD, PhD, MGH/HST Athinoula A. Martinos Center for Biomedical Imaging, 149 13th St, Charlestown, MA 02129 ()
| | - Jouko Miettunen
- Turku PET Centre, Turku University Hospital, Turku, Finland (Drs Tuominen, Hirvonen, and Hietala); Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA (Dr Tuominen); Center for Life Course Health Research, University of Oulu, Finland & Medical Research Center (MRC) Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland (Dr Miettunen); Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland, Galway, Ireland (Dr Cannon); Janssen Research & Development, LLC, of Johnson & Johnson, Titusville, NJ (Dr Drevets); Neurobiology Research Unit, Rigshospitalet, Denmark (Dr Knudsen); Center for Integrated Molecular Brain Imaging, Rigshospitalet, Denmark (Dr Frokjaer and Mr Jensen); Department of Radiology, University of Turku, Turku, Finland (Dr Hirvonen); Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institute for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Ichise, Takano, and Suhara); IBS, Unit of Personality, Work and Health Psychology, University of Helsinki, Helsinki, Finland (Dr Keltikangas-Järvinen); Department of Psychology, Southern Illinois University, Carbondale, Illinois (Dr Klaver); Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (Dr Knudsen); Center for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Dr Takano); Department of Psychiatry, University of Turku, Turku, Finland (Dr Hietala)
| | - Dara M Cannon
- Turku PET Centre, Turku University Hospital, Turku, Finland (Drs Tuominen, Hirvonen, and Hietala); Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA (Dr Tuominen); Center for Life Course Health Research, University of Oulu, Finland & Medical Research Center (MRC) Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland (Dr Miettunen); Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland, Galway, Ireland (Dr Cannon); Janssen Research & Development, LLC, of Johnson & Johnson, Titusville, NJ (Dr Drevets); Neurobiology Research Unit, Rigshospitalet, Denmark (Dr Knudsen); Center for Integrated Molecular Brain Imaging, Rigshospitalet, Denmark (Dr Frokjaer and Mr Jensen); Department of Radiology, University of Turku, Turku, Finland (Dr Hirvonen); Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institute for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Ichise, Takano, and Suhara); IBS, Unit of Personality, Work and Health Psychology, University of Helsinki, Helsinki, Finland (Dr Keltikangas-Järvinen); Department of Psychology, Southern Illinois University, Carbondale, Illinois (Dr Klaver); Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (Dr Knudsen); Center for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Dr Takano); Department of Psychiatry, University of Turku, Turku, Finland (Dr Hietala)
| | - Wayne C Drevets
- Turku PET Centre, Turku University Hospital, Turku, Finland (Drs Tuominen, Hirvonen, and Hietala); Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA (Dr Tuominen); Center for Life Course Health Research, University of Oulu, Finland & Medical Research Center (MRC) Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland (Dr Miettunen); Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland, Galway, Ireland (Dr Cannon); Janssen Research & Development, LLC, of Johnson & Johnson, Titusville, NJ (Dr Drevets); Neurobiology Research Unit, Rigshospitalet, Denmark (Dr Knudsen); Center for Integrated Molecular Brain Imaging, Rigshospitalet, Denmark (Dr Frokjaer and Mr Jensen); Department of Radiology, University of Turku, Turku, Finland (Dr Hirvonen); Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institute for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Ichise, Takano, and Suhara); IBS, Unit of Personality, Work and Health Psychology, University of Helsinki, Helsinki, Finland (Dr Keltikangas-Järvinen); Department of Psychology, Southern Illinois University, Carbondale, Illinois (Dr Klaver); Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (Dr Knudsen); Center for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Dr Takano); Department of Psychiatry, University of Turku, Turku, Finland (Dr Hietala)
| | - Vibe G Frokjaer
- Turku PET Centre, Turku University Hospital, Turku, Finland (Drs Tuominen, Hirvonen, and Hietala); Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA (Dr Tuominen); Center for Life Course Health Research, University of Oulu, Finland & Medical Research Center (MRC) Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland (Dr Miettunen); Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland, Galway, Ireland (Dr Cannon); Janssen Research & Development, LLC, of Johnson & Johnson, Titusville, NJ (Dr Drevets); Neurobiology Research Unit, Rigshospitalet, Denmark (Dr Knudsen); Center for Integrated Molecular Brain Imaging, Rigshospitalet, Denmark (Dr Frokjaer and Mr Jensen); Department of Radiology, University of Turku, Turku, Finland (Dr Hirvonen); Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institute for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Ichise, Takano, and Suhara); IBS, Unit of Personality, Work and Health Psychology, University of Helsinki, Helsinki, Finland (Dr Keltikangas-Järvinen); Department of Psychology, Southern Illinois University, Carbondale, Illinois (Dr Klaver); Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (Dr Knudsen); Center for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Dr Takano); Department of Psychiatry, University of Turku, Turku, Finland (Dr Hietala)
| | - Jussi Hirvonen
- Turku PET Centre, Turku University Hospital, Turku, Finland (Drs Tuominen, Hirvonen, and Hietala); Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA (Dr Tuominen); Center for Life Course Health Research, University of Oulu, Finland & Medical Research Center (MRC) Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland (Dr Miettunen); Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland, Galway, Ireland (Dr Cannon); Janssen Research & Development, LLC, of Johnson & Johnson, Titusville, NJ (Dr Drevets); Neurobiology Research Unit, Rigshospitalet, Denmark (Dr Knudsen); Center for Integrated Molecular Brain Imaging, Rigshospitalet, Denmark (Dr Frokjaer and Mr Jensen); Department of Radiology, University of Turku, Turku, Finland (Dr Hirvonen); Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institute for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Ichise, Takano, and Suhara); IBS, Unit of Personality, Work and Health Psychology, University of Helsinki, Helsinki, Finland (Dr Keltikangas-Järvinen); Department of Psychology, Southern Illinois University, Carbondale, Illinois (Dr Klaver); Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (Dr Knudsen); Center for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Dr Takano); Department of Psychiatry, University of Turku, Turku, Finland (Dr Hietala)
| | - Masanori Ichise
- Turku PET Centre, Turku University Hospital, Turku, Finland (Drs Tuominen, Hirvonen, and Hietala); Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA (Dr Tuominen); Center for Life Course Health Research, University of Oulu, Finland & Medical Research Center (MRC) Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland (Dr Miettunen); Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland, Galway, Ireland (Dr Cannon); Janssen Research & Development, LLC, of Johnson & Johnson, Titusville, NJ (Dr Drevets); Neurobiology Research Unit, Rigshospitalet, Denmark (Dr Knudsen); Center for Integrated Molecular Brain Imaging, Rigshospitalet, Denmark (Dr Frokjaer and Mr Jensen); Department of Radiology, University of Turku, Turku, Finland (Dr Hirvonen); Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institute for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Ichise, Takano, and Suhara); IBS, Unit of Personality, Work and Health Psychology, University of Helsinki, Helsinki, Finland (Dr Keltikangas-Järvinen); Department of Psychology, Southern Illinois University, Carbondale, Illinois (Dr Klaver); Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (Dr Knudsen); Center for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Dr Takano); Department of Psychiatry, University of Turku, Turku, Finland (Dr Hietala)
| | - Peter S Jensen
- Turku PET Centre, Turku University Hospital, Turku, Finland (Drs Tuominen, Hirvonen, and Hietala); Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA (Dr Tuominen); Center for Life Course Health Research, University of Oulu, Finland & Medical Research Center (MRC) Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland (Dr Miettunen); Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland, Galway, Ireland (Dr Cannon); Janssen Research & Development, LLC, of Johnson & Johnson, Titusville, NJ (Dr Drevets); Neurobiology Research Unit, Rigshospitalet, Denmark (Dr Knudsen); Center for Integrated Molecular Brain Imaging, Rigshospitalet, Denmark (Dr Frokjaer and Mr Jensen); Department of Radiology, University of Turku, Turku, Finland (Dr Hirvonen); Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institute for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Ichise, Takano, and Suhara); IBS, Unit of Personality, Work and Health Psychology, University of Helsinki, Helsinki, Finland (Dr Keltikangas-Järvinen); Department of Psychology, Southern Illinois University, Carbondale, Illinois (Dr Klaver); Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (Dr Knudsen); Center for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Dr Takano); Department of Psychiatry, University of Turku, Turku, Finland (Dr Hietala)
| | - Liisa Keltikangas-Järvinen
- Turku PET Centre, Turku University Hospital, Turku, Finland (Drs Tuominen, Hirvonen, and Hietala); Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA (Dr Tuominen); Center for Life Course Health Research, University of Oulu, Finland & Medical Research Center (MRC) Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland (Dr Miettunen); Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland, Galway, Ireland (Dr Cannon); Janssen Research & Development, LLC, of Johnson & Johnson, Titusville, NJ (Dr Drevets); Neurobiology Research Unit, Rigshospitalet, Denmark (Dr Knudsen); Center for Integrated Molecular Brain Imaging, Rigshospitalet, Denmark (Dr Frokjaer and Mr Jensen); Department of Radiology, University of Turku, Turku, Finland (Dr Hirvonen); Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institute for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Ichise, Takano, and Suhara); IBS, Unit of Personality, Work and Health Psychology, University of Helsinki, Helsinki, Finland (Dr Keltikangas-Järvinen); Department of Psychology, Southern Illinois University, Carbondale, Illinois (Dr Klaver); Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (Dr Knudsen); Center for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Dr Takano); Department of Psychiatry, University of Turku, Turku, Finland (Dr Hietala)
| | - Jacqueline M Klaver
- Turku PET Centre, Turku University Hospital, Turku, Finland (Drs Tuominen, Hirvonen, and Hietala); Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA (Dr Tuominen); Center for Life Course Health Research, University of Oulu, Finland & Medical Research Center (MRC) Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland (Dr Miettunen); Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland, Galway, Ireland (Dr Cannon); Janssen Research & Development, LLC, of Johnson & Johnson, Titusville, NJ (Dr Drevets); Neurobiology Research Unit, Rigshospitalet, Denmark (Dr Knudsen); Center for Integrated Molecular Brain Imaging, Rigshospitalet, Denmark (Dr Frokjaer and Mr Jensen); Department of Radiology, University of Turku, Turku, Finland (Dr Hirvonen); Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institute for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Ichise, Takano, and Suhara); IBS, Unit of Personality, Work and Health Psychology, University of Helsinki, Helsinki, Finland (Dr Keltikangas-Järvinen); Department of Psychology, Southern Illinois University, Carbondale, Illinois (Dr Klaver); Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (Dr Knudsen); Center for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Dr Takano); Department of Psychiatry, University of Turku, Turku, Finland (Dr Hietala)
| | - Gitte M Knudsen
- Turku PET Centre, Turku University Hospital, Turku, Finland (Drs Tuominen, Hirvonen, and Hietala); Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA (Dr Tuominen); Center for Life Course Health Research, University of Oulu, Finland & Medical Research Center (MRC) Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland (Dr Miettunen); Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland, Galway, Ireland (Dr Cannon); Janssen Research & Development, LLC, of Johnson & Johnson, Titusville, NJ (Dr Drevets); Neurobiology Research Unit, Rigshospitalet, Denmark (Dr Knudsen); Center for Integrated Molecular Brain Imaging, Rigshospitalet, Denmark (Dr Frokjaer and Mr Jensen); Department of Radiology, University of Turku, Turku, Finland (Dr Hirvonen); Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institute for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Ichise, Takano, and Suhara); IBS, Unit of Personality, Work and Health Psychology, University of Helsinki, Helsinki, Finland (Dr Keltikangas-Järvinen); Department of Psychology, Southern Illinois University, Carbondale, Illinois (Dr Klaver); Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (Dr Knudsen); Center for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Dr Takano); Department of Psychiatry, University of Turku, Turku, Finland (Dr Hietala)
| | - Akihiro Takano
- Turku PET Centre, Turku University Hospital, Turku, Finland (Drs Tuominen, Hirvonen, and Hietala); Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA (Dr Tuominen); Center for Life Course Health Research, University of Oulu, Finland & Medical Research Center (MRC) Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland (Dr Miettunen); Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland, Galway, Ireland (Dr Cannon); Janssen Research & Development, LLC, of Johnson & Johnson, Titusville, NJ (Dr Drevets); Neurobiology Research Unit, Rigshospitalet, Denmark (Dr Knudsen); Center for Integrated Molecular Brain Imaging, Rigshospitalet, Denmark (Dr Frokjaer and Mr Jensen); Department of Radiology, University of Turku, Turku, Finland (Dr Hirvonen); Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institute for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Ichise, Takano, and Suhara); IBS, Unit of Personality, Work and Health Psychology, University of Helsinki, Helsinki, Finland (Dr Keltikangas-Järvinen); Department of Psychology, Southern Illinois University, Carbondale, Illinois (Dr Klaver); Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (Dr Knudsen); Center for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Dr Takano); Department of Psychiatry, University of Turku, Turku, Finland (Dr Hietala)
| | - Tetsuya Suhara
- Turku PET Centre, Turku University Hospital, Turku, Finland (Drs Tuominen, Hirvonen, and Hietala); Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA (Dr Tuominen); Center for Life Course Health Research, University of Oulu, Finland & Medical Research Center (MRC) Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland (Dr Miettunen); Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland, Galway, Ireland (Dr Cannon); Janssen Research & Development, LLC, of Johnson & Johnson, Titusville, NJ (Dr Drevets); Neurobiology Research Unit, Rigshospitalet, Denmark (Dr Knudsen); Center for Integrated Molecular Brain Imaging, Rigshospitalet, Denmark (Dr Frokjaer and Mr Jensen); Department of Radiology, University of Turku, Turku, Finland (Dr Hirvonen); Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institute for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Ichise, Takano, and Suhara); IBS, Unit of Personality, Work and Health Psychology, University of Helsinki, Helsinki, Finland (Dr Keltikangas-Järvinen); Department of Psychology, Southern Illinois University, Carbondale, Illinois (Dr Klaver); Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (Dr Knudsen); Center for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Dr Takano); Department of Psychiatry, University of Turku, Turku, Finland (Dr Hietala)
| | - Jarmo Hietala
- Turku PET Centre, Turku University Hospital, Turku, Finland (Drs Tuominen, Hirvonen, and Hietala); Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA (Dr Tuominen); Center for Life Course Health Research, University of Oulu, Finland & Medical Research Center (MRC) Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland (Dr Miettunen); Centre for Neuroimaging & Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland, Galway, Ireland (Dr Cannon); Janssen Research & Development, LLC, of Johnson & Johnson, Titusville, NJ (Dr Drevets); Neurobiology Research Unit, Rigshospitalet, Denmark (Dr Knudsen); Center for Integrated Molecular Brain Imaging, Rigshospitalet, Denmark (Dr Frokjaer and Mr Jensen); Department of Radiology, University of Turku, Turku, Finland (Dr Hirvonen); Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institute for Quantum and Radiological Science and Technology, Chiba, Japan (Drs Ichise, Takano, and Suhara); IBS, Unit of Personality, Work and Health Psychology, University of Helsinki, Helsinki, Finland (Dr Keltikangas-Järvinen); Department of Psychology, Southern Illinois University, Carbondale, Illinois (Dr Klaver); Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark (Dr Knudsen); Center for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (Dr Takano); Department of Psychiatry, University of Turku, Turku, Finland (Dr Hietala)
| |
Collapse
|
13
|
Abstract
OBJECTIVE To assess personality traits using the Temperament and Character Inventory (TCI) in a group of 63 previously diagnosed ADHD patients and 68 population controls and investigate the impact of common comorbid psychiatric disorders on these personality measures. METHOD Psychiatric comorbidity was assessed with the Mini International Neuropsychiatric Interview Plus and personality traits by the TCI. RESULTS The patient group had significantly higher scores on the TCI dimensions Harm avoidance and Novelty seeking compared with the control group. However, when adjusting for comorbid anxiety and depressive disorder, the ADHD group no longer showed higher Harm avoidance than the control group. The difference in Novelty seeking between the patient and control groups was correlated with lifetime diagnosis of antisocial personality disorder (ASPD). CONCLUSION It is important to take comorbid psychiatric disorders into account while investigating personality traits in ADHD.
Collapse
Affiliation(s)
| | - Jan Haavik
- University of Bergen, Norway Haukeland University Hospital, Bergen, Norway
| | - Anne Halmøy
- University of Bergen, Norway Haukeland University Hospital, Bergen, Norway
| |
Collapse
|
14
|
Zientek F, Winter K, Müller A, Rullmann M, Luthardt J, Becker GA, Bresch A, Patt M, Sabri O, Hilbert A, Hesse S. Effortful control as a dimension of temperament is negatively associated with prefrontal serotonin transporter availability in obese and non-obese individuals. Eur J Neurosci 2016; 44:2460-2466. [PMID: 27519298 DOI: 10.1111/ejn.13362] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2016] [Revised: 07/26/2016] [Accepted: 08/02/2016] [Indexed: 11/25/2022]
Abstract
There is evidence that temperamental factors are associated with obesity; however, the biological mechanism of such association remains elusive. We aimed to investigate a possible association between serotonin transmission and regulative temperament in obese and non-obese individuals by using positron emission tomography (PET) imaging of serotonin transporters (SERT) and the Adult Temperament Questionnaire. Twenty-nine obese individuals with body mass index (BMI) ≥ 35 kg/m2 and 13 non-obese controls (BMI < 30 kg/m2 ) underwent PET with [11 C]-labeled DASB (highly selective for SERT) and self-completed the Effortful Control (EC) scale of the Adult Temperament Questionnaire-Short Form (ATQ). With the help of this questionnaire, we aimed to assess the capacity of self-regulation. Overall, for obese and non-obese individuals together, VOI-based (volume of interest) analysis showed significant negative correlations between SERT BPND and ATQ-EC AC (Activation Control) subscale in several brain regions (all r ≤ -0.47). Obese and non-obese individuals separated showed equally strong positive, but non-significant correlations. The analysis did not reveal any significant correlations of SERT availability and ATQ-EC IC (Inhibitory Control) or ATQ-EC AtC (Attentional Control) subscale within and between the two groups. The results indicate that regulative temperament - particularly the capacity to mitigate negatively toned impulses and to resist inappropriate avoidance behavior - might be associated with the prefrontal serotonergic system.
Collapse
Affiliation(s)
- Franziska Zientek
- Integrated Treatment and Research Centre (IFB) Adiposity Diseases, Leipzig University Medical Centre, Leipzig, Germany. .,Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103, Leipzig, Germany.
| | - Karsten Winter
- Translational Centre for Regenerative Medicine (TRM), University of Leipzig, Leipzig, Germany
| | - Astrid Müller
- Department of Psychosomatic Medicine and Psychotherapy, Hannover Medical School, Hannover, Germany
| | - Michael Rullmann
- Integrated Treatment and Research Centre (IFB) Adiposity Diseases, Leipzig University Medical Centre, Leipzig, Germany
| | - Julia Luthardt
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103, Leipzig, Germany
| | - Georg-Alexander Becker
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103, Leipzig, Germany
| | - Anke Bresch
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103, Leipzig, Germany
| | - Marianne Patt
- Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103, Leipzig, Germany
| | - Osama Sabri
- Integrated Treatment and Research Centre (IFB) Adiposity Diseases, Leipzig University Medical Centre, Leipzig, Germany.,Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103, Leipzig, Germany
| | - Anja Hilbert
- Integrated Treatment and Research Centre (IFB) Adiposity Diseases, Leipzig University Medical Centre, Leipzig, Germany.,Department of Medical Psychology and Medical Sociology, University of Leipzig Medical Center, Leipzig, Germany
| | - Swen Hesse
- Integrated Treatment and Research Centre (IFB) Adiposity Diseases, Leipzig University Medical Centre, Leipzig, Germany.,Department of Nuclear Medicine, University of Leipzig, Liebigstraße 18, 04103, Leipzig, Germany
| |
Collapse
|
15
|
Valente TS, Baldi F, Sant’Anna AC, Albuquerque LG, Paranhos da Costa MJR. Genome-Wide Association Study between Single Nucleotide Polymorphisms and Flight Speed in Nellore Cattle. PLoS One 2016; 11:e0156956. [PMID: 27300296 PMCID: PMC4907449 DOI: 10.1371/journal.pone.0156956] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2016] [Accepted: 05/23/2016] [Indexed: 12/17/2022] Open
Abstract
Introduction Cattle temperament is an important factor that affects the profitability of beef cattle enterprises, due to its relationship with productivity traits, animal welfare and labor safety. Temperament is a complex phenotype often assessed by measuring a series of behavioral traits, which result from the effects of multiple environmental and genetic factors, and their interactions. The aims of this study were to perform a genome-wide association study and detect genomic regions, potential candidate genes and their biological mechanisms underlying temperament, measured by flight speed (FS) test in Nellore cattle. Materials and Methods The genome-wide association study (GWAS) was performed using a single-step procedure (ssGBLUP) which combined simultaneously all 16,600 phenotypes from genotyped and non-genotyped animals, full pedigree information of 162,645 animals and 1,384 genotyped animals in one step. The animals were genotyped with High Density Bovine SNP BeadChip which contains 777,962 SNP markers. After quality control (QC) a total of 455,374 SNPs remained. Results Heritability estimated for FS was 0.21 ± 0.02. Consecutive SNPs explaining 1% or more of the total additive genetic variance were considered as windows associated with FS. Nine candidate regions located on eight different Bos taurus chromosomes (BTA) (1 at 73 Mb, 2 at 65 Mb, 5 at 22 Mb and 119 Mb, 9 at 98 Mb, 11 at 67 Mb, 15 at 16 Mb, 17 at 63 Kb, and 26 at 47 Mb) were identified. The candidate genes identified in these regions were NCKAP5 (BTA2), PARK2 (BTA9), ANTXR1 (BTA11), GUCY1A2 (BTA15), CPE (BTA17) and DOCK1 (BTA26). Among these genes PARK2, GUCY1A2, CPE and DOCK1 are related to dopaminergic system, memory formation, biosynthesis of peptide hormone and neurotransmitter and brain development, respectively. Conclusions Our findings allowed us to identify nine genomic regions (SNP windows) associated with beef cattle temperament, measured by FS test. Within these windows, six promising candidate genes and their biological functions were identified. These results may contribute to a better comprehension into the genetic control of temperament expression in Nellore cattle.
Collapse
Affiliation(s)
- Tiago Silva Valente
- Universidade Estadual Paulista (Unesp), Faculdade de Ciências Agrárias e Veterinárias, Departamento de Zootecnia, Via de Acesso Professor Paulo Donato Castellane, Jaboticabal, SP 14.884-900, Brazil
| | - Fernando Baldi
- Universidade Estadual Paulista (Unesp), Faculdade de Ciências Agrárias e Veterinárias, Departamento de Zootecnia, Via de Acesso Professor Paulo Donato Castellane, Jaboticabal, SP 14.884-900, Brazil
| | - Aline Cristina Sant’Anna
- Universidade Federal de Juiz de Fora (UFJF), Instituto de Ciências Biológicas, Departamento de Zoologia, Rua José Lourenço Kelmer, Juiz de Fora, MG 36.036-900, Brazil
| | - Lucia Galvão Albuquerque
- Universidade Estadual Paulista (Unesp), Faculdade de Ciências Agrárias e Veterinárias, Departamento de Zootecnia, Via de Acesso Professor Paulo Donato Castellane, Jaboticabal, SP 14.884-900, Brazil
| | - Mateus José Rodrigues Paranhos da Costa
- Universidade Estadual Paulista (Unesp), Faculdade de Ciências Agrárias e Veterinárias, Departamento de Zootecnia, Via de Acesso Professor Paulo Donato Castellane, Jaboticabal, SP 14.884-900, Brazil
- * E-mail:
| |
Collapse
|
16
|
Galindo L, Pastoriza F, Bergé D, Mané A, Picado M, Bulbena A, Robledo P, Pérez V, Vilarroya O, Cloninger CR. Association between neurological soft signs, temperament and character in patients with schizophrenia and non-psychotic relatives. PeerJ 2016; 4:e1651. [PMID: 27168955 PMCID: PMC4860298 DOI: 10.7717/peerj.1651] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2015] [Accepted: 01/12/2016] [Indexed: 11/26/2022] Open
Abstract
The heritability of schizophrenia and most personality traits has been well established, but the role of personality in susceptibility to schizophrenia remains uncertain. The aim of this study was to test for an association between personality traits and Neurological Soft Signs (NSS), a well-known biological marker of schizophrenia, in non-psychotic relatives of patients with schizophrenia. For this purpose, we evaluated the NSS scale and personality measured by the Temperament and Character inventory (TCI-R) in three groups of subjects: 29 patients with schizophrenia, 24 unaffected relatives and 37 controls. The results showed that patients with schizophrenia were more asocial (higher harm avoidance and lower reward dependence), more perseverative (higher persistence), and more schizotypal (lower self-directedness and cooperativeness, higher self-transcendence). The unaffected relatives showed higher harm avoidance, lower self-directedness and cooperativeness than the healthy controls. Higher NSS scores and sub-scores were found in patients and non-psychotic relatives compared with the controls. Among all the patients, total NSS scores were positively correlated with harm avoidance but negatively correlated with novelty seeking and persistence. Total NSS were also correlated with low scores on self-directedness and cooperativeness, which are indicators of personality disorder. Our results show that susceptibility to NSS and to schizophrenia are both related to individual differences in the temperament and character features in non-psychotic relatives of patients with schizophrenia. High harm avoidance, low persistence, low self-directedness and low cooperativeness contribute to both the risk of NSS and schizophrenia. These findings highlight the value of using both assessments to study high risk populations.
Collapse
Affiliation(s)
- Liliana Galindo
- Neuropsychiatry and Addiction Institute, Parc de Salut Mar, Barcelona, Spain; Neurosciences Research Programme, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain; Departament de Psiquiatria i Medicina Legal, Universitat Autónoma de Barcelona, Cerdanyola del Vallés, Spain; Red de Trastornos Adictivos, RETIC, Spain
| | - Francisco Pastoriza
- Neurosciences Research Programme, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain; Departament de Psiquiatria i Medicina Legal, Universitat Autónoma de Barcelona, Cerdanyola del Vallés, Spain
| | - Daniel Bergé
- Neuropsychiatry and Addiction Institute, Parc de Salut Mar, Barcelona, Spain; Neurosciences Research Programme, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain; Departament de Psiquiatria i Medicina Legal, Universitat Autónoma de Barcelona, Cerdanyola del Vallés, Spain; Neuropharmacology, Universitat Pompeu Fabra, Barcelona, Spain
| | - Anna Mané
- Neuropsychiatry and Addiction Institute, Parc de Salut Mar, Barcelona, Spain; Neurosciences Research Programme, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM G21, Spain
| | - Marisol Picado
- Neurosciences Research Programme, Hospital del Mar Medical Research Institute (IMIM) , Barcelona , Spain
| | - Antonio Bulbena
- Neuropsychiatry and Addiction Institute, Parc de Salut Mar, Barcelona, Spain; Neurosciences Research Programme, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain; Departament de Psiquiatria i Medicina Legal, Universitat Autónoma de Barcelona, Cerdanyola del Vallés, Spain; Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM G21, Spain
| | - Patricia Robledo
- Neurosciences Research Programme, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain; Neuropharmacology, Universitat Pompeu Fabra, Barcelona, Spain
| | - Victor Pérez
- Neuropsychiatry and Addiction Institute, Parc de Salut Mar, Barcelona, Spain; Neurosciences Research Programme, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain; Departament de Psiquiatria i Medicina Legal, Universitat Autónoma de Barcelona, Cerdanyola del Vallés, Spain; Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM G21, Spain
| | - Oscar Vilarroya
- Neurosciences Research Programme, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain; Departament de Psiquiatria i Medicina Legal, Universitat Autónoma de Barcelona, Cerdanyola del Vallés, Spain
| | - Claude Robert Cloninger
- Department of Psychiatry and Genetics, Washington University in St. Louis , Saint Louis, MO , United States
| |
Collapse
|
17
|
Udina M, Navinés R, Egmond E, Oriolo G, Langohr K, Gimenez D, Valdés M, Gómez-Gil E, Grande I, Gratacós M, Kapczinski F, Artigas F, Vieta E, Solà R, Martín-Santos R. Glucocorticoid Receptors, Brain-Derived Neurotrophic Factor, Serotonin and Dopamine Neurotransmission are Associated with Interferon-Induced Depression. Int J Neuropsychopharmacol 2016; 19:pyv135. [PMID: 26721949 PMCID: PMC4851270 DOI: 10.1093/ijnp/pyv135] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2015] [Revised: 11/24/2015] [Accepted: 12/11/2015] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND The role of inflammation in mood disorders has received increased attention. There is substantial evidence that cytokine therapies, such as interferon alpha (IFN-alpha), can induce depressive symptoms. Indeed, proinflammatory cytokines change brain function in several ways, such as altering neurotransmitters, the glucocorticoid axis, and apoptotic mechanisms. This study aimed to evaluate the impact on mood of initiating IFN-alpha and ribavirin treatment in a cohort of patients with chronic hepatitis C. We investigated clinical, personality, and functional genetic variants associated with cytokine-induced depression. METHODS We recruited 344 Caucasian outpatients with chronic hepatitis C, initiating IFN-alpha and ribavirin therapy. All patients were euthymic at baseline according to DSM-IV-R criteria. Patients were assessed at baseline and 4, 12, 24, and 48 weeks after treatment initiation using the Patient Health Questionnaire (PHQ), the Hospital Anxiety and Depression Scale (HADS), and the Temperament and Character Inventory (TCI). We genotyped several functional polymorphisms of interleukin-28 (IL28B), indoleamine 2,3-dioxygenase (IDO-1), serotonin receptor-1A (HTR1A), catechol-O-methyl transferase (COMT), glucocorticoid receptors (GCR1 and GCR2), brain-derived neurotrophic factor (BDNF), and FK506 binding protein 5 (FKBP5) genes. A survival analysis was performed, and the Cox proportional hazards model was used for the multivariate analysis. RESULTS The cumulative incidence of depression was 0.35 at week 24 and 0.46 at week 48. The genotypic distributions were in Hardy-Weinberg equilibrium. Older age (p = 0.018, hazard ratio [HR] per 5 years = 1.21), presence of depression history (p = 0.0001, HR = 2.38), and subthreshold depressive symptoms at baseline (p = 0.005, HR = 1.13) increased the risk of IFN-induced depression. So too did TCI personality traits, with high scores on fatigability (p = 0.0037, HR = 1.17), impulsiveness (p = 0.0200 HR = 1.14), disorderliness (p = 0.0339, HR = 1.11), and low scores on extravagance (p = 0.0040, HR = 0.85). An interaction between HTR1A and COMT genes was found. Patients carrying the G allele of HTR1A plus the Met substitution of the COMT polymorphism had a greater risk for depression during antiviral treatment (HR = 3.83) than patients with the CC (HTR1A) and Met allele (COMT) genotypes. Patients carrying the HTR1A CC genotype and the COMT Val/Val genotype (HR = 3.25) had a higher risk of depression than patients with the G allele (HTR1A) and the Val/Val genotype. Moreover, functional variants of the GCR1 (GG genotype: p = 0.0436, HR = 1.88) and BDNF genes (Val/Val genotype: p = 0.0453, HR = 0.55) were associated with depression. CONCLUSIONS The results of the study support the theory that IFN-induced depression is associated with a complex pathophysiological background, including serotonergic and dopaminergic neurotransmission as well as glucocorticoid and neurotrophic factors. These findings may help to improve the management of patients on antiviral treatment and broaden our understanding of the pathogenesis of mood disorders.
Collapse
MESH Headings
- Adult
- Antiviral Agents/therapeutic use
- Brain-Derived Neurotrophic Factor/genetics
- Catechol O-Methyltransferase/genetics
- Depression/chemically induced
- Depression/epidemiology
- Depression/genetics
- Depression/immunology
- Female
- Genetic Predisposition to Disease
- Hepatitis C, Chronic/drug therapy
- Hepatitis C, Chronic/epidemiology
- Hepatitis C, Chronic/genetics
- Hepatitis C, Chronic/psychology
- Humans
- Incidence
- Indoleamine-Pyrrole 2,3,-Dioxygenase/genetics
- Interferon-alpha/adverse effects
- Interferon-alpha/therapeutic use
- Interferons
- Interleukins/genetics
- Male
- Middle Aged
- Polymorphism, Single Nucleotide
- Prospective Studies
- Receptor, Serotonin, 5-HT1A/genetics
- Receptors, Glucocorticoid/genetics
- Ribavirin/therapeutic use
- Tacrolimus Binding Proteins/genetics
- Treatment Outcome
- White People/genetics
Collapse
Affiliation(s)
- M Udina
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - R Navinés
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - E Egmond
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - G Oriolo
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - K Langohr
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - D Gimenez
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - M Valdés
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - E Gómez-Gil
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - I Grande
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - M Gratacós
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - F Kapczinski
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - F Artigas
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - E Vieta
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - R Solà
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - R Martín-Santos
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| |
Collapse
|
18
|
Kambeitz JP, Howes OD. The serotonin transporter in depression: Meta-analysis of in vivo and post mortem findings and implications for understanding and treating depression. J Affect Disord 2015; 186:358-66. [PMID: 26281039 DOI: 10.1016/j.jad.2015.07.034] [Citation(s) in RCA: 57] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/10/2015] [Revised: 06/29/2015] [Accepted: 07/28/2015] [Indexed: 12/23/2022]
Abstract
BACKGROUND Altered serotonin transporter levels have been reported in blood and brain of patients with major depressive disorders. However, the strength and consistency of the evidence for altered serotonin transporter availability in major depressive disorder is not clear. METHODS To address this, a comprehensive meta-analysis was conducted of all available in vivo neuroimaging and post mortem studies reporting serotonin transporter availability in patients with depression compared with healthy controls. RESULTS The final sample consisted of fifty (n=27 in vivo and n=25 post mortem) studies including 877 patients with depression (mean age: 42.9 years) and 968 healthy controls (mean age: 42.7 years). In vivo neuroimaging studies indicated reduced serotonin transporter binding in the striatum (g=-0.39, p=0.01), the amygdala (g=-0.37, p=0.01) and the brainstem (g=-0.31, p=0.01), including the midbrain (g=-0.27, p=0.02), but no significant alteration in the thalamus or the hippocampus. The post mortem findings indicated no significant change in serotonin transporter binding in depression in the brainstem (p=0.64), the frontal cortex (p=0.75) and the hippocampus (p=0.32, corrected for publication bias). Although there were too few studies for a meta-analysis, the post mortem studies in the amygdala and striatum showed reduced SERT binding in MDD in absolute terms, consistent with the imaging findings. LIMITATIONS A number of potential factors might have biased the results of the present meta-analysis such as the imaging modality (post mortem or in vivo neuroimaging), partial volume effects, susceptibility of some radiotracers to synaptic serotonin levels or binding to other monoamine transporters. CONCLUSIONS The results indicate that serotonin transporter availability in depressed patients is reduced in key regions of the limbic system. This provides direct support for the serotonin hypothesis of depression, and underlines the importance of the serotonin transporter as a target of pharmacological treatments.
Collapse
Affiliation(s)
- Joseph P Kambeitz
- Department of Psychosis Studies, Institute of Psychiatry, King's College London, England, United Kingdom; Department of Psychiatry, Ludwig-Maximilians-University Munich, Germany
| | - Oliver D Howes
- Department of Psychosis Studies, Institute of Psychiatry, King's College London, England, United Kingdom; Psychiatric Imaging Group, Medical Research Council Clinical Sciences Centre, Imperial College London, Hammersmith Hospital, United Kingdom.
| |
Collapse
|
19
|
Kim JH, Son YD, Kim JH, Choi EJ, Lee SY, Joo YH, Kim YB, Cho ZH. Self-transcendence trait and its relationship with in vivo serotonin transporter availability in brainstem raphe nuclei: An ultra-high resolution PET-MRI study. Brain Res 2015; 1629:63-71. [PMID: 26459992 DOI: 10.1016/j.brainres.2015.10.006] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2015] [Revised: 09/08/2015] [Accepted: 10/01/2015] [Indexed: 01/12/2023]
Abstract
Self-transcendence is an inherent human personality trait relating to the experience of spiritual aspects of the self. We examined the relationship between self-transcendence and serotonin transporter (SERT) availability in brainstem raphe nuclei, which are collections of five different serotonergic nuclei with rostro-caudal extension, using ultra-high resolution magnetic resonance imaging (MRI) and positron emission tomography (PET) with (11)C-3-amino-4-(2-dimethylaminomethylphenylthio)benzonitrile ([(11)C]DASB) to elucidate potential roles of serotonergic neuronal activities in this personality trait. Sixteen healthy subjects completed 7.0T MRI and High Resolution Research Tomograph (HRRT) PET. The regions of interest (ROIs) included the dorsal raphe nucleus (R1), median raphe nucleus (R2), raphe pontis (R3), and the caudal raphe nuclei (R4 and R5). For the estimation of SERT availability, the binding potential (BPND) was derived using the simplified reference tissue model (SRTM2). The Temperament and Character Inventory was used to measure self-transcendence. The analysis revealed that the self-transcendence total score had a significant negative correlation with the [(11)C]DASB BPND in the caudal raphe (R5). The subscale score for spiritual acceptance was significantly negatively correlated with the [(11)C]DASB BPND in the median raphe nucleus (R2). The results indicate that the self-transcendence trait is associated with SERT availability in specific raphe subnuclei, suggesting that the serotonin system may serve as an important biological basis for human self-transcendence. Based on the connections of these nuclei with cortico-limbic and visceral autonomic structures, the functional activity of these nuclei and their related neural circuitry may play a crucial role in the manifestation of self-transcendence.
Collapse
|
20
|
Tomita T, Kaneda A, Nakagami T, Kaneko S, Yasui-Furukori N. Changes in the Temperament and Character Inventory dimensions after paroxetine treatment in patients with major depressive disorder. Hum Psychopharmacol 2015; 30:334-40. [PMID: 25845342 DOI: 10.1002/hup.2479] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/11/2014] [Revised: 01/03/2015] [Accepted: 03/03/2015] [Indexed: 01/19/2023]
Abstract
Previous studies have reported changes in the dimensions of the Temperament and Character Inventory (TCI) after patients with major depressive disorder are treated. We aimed to investigate the changes in the TCI dimensions after paroxetine treatment in patients with major depressive disorder. Forty-eight patients were enrolled in this study and were treated with 10-40 mg/day of paroxetine for 6 weeks. The TCI was completed twice, at weeks 0 and 6. We used the Montgomery-Asberg Depression Rating Scale (MADRS) to evaluate patients. The participants were divided into three groups (responders, non-responders, and early responders) based on treatment response. The scores of each dimension of the TCI were compared before and after treatment using repeated-measures two-way analyses of variance. In the responders group (n = 24), no TCI dimension scores changed significantly during treatment, but the interaction between sex and MADRS score change was significantly associated with the results. In the non-responders group (n = 15), the self-directedness score increased significantly during the treatment period (p = 0.000), and the change in MADRS score significantly affected the results. In the early responders group (n = 9), no TCI dimension scores changed significantly during treatment. The results of the present study may reveal a possible correlation between paroxetine treatment and changes in personality traits.
Collapse
Affiliation(s)
- Tetsu Tomita
- Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan
| | - Ayako Kaneda
- Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan
| | - Taku Nakagami
- Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan
| | - Sunao Kaneko
- Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan
| | - Norio Yasui-Furukori
- Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan
| |
Collapse
|
21
|
Altunayoglu Cakmak V, Gazioglu S, Can Usta N, Ozkorumak E, Ayar A, Topbas M, Boz C. Evaluation of temperament and character features as risk factors for depressive symptoms in patients with restless legs syndrome. J Clin Neurol 2014; 10:320-7. [PMID: 25324881 PMCID: PMC4198713 DOI: 10.3988/jcn.2014.10.4.320] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2013] [Revised: 05/10/2014] [Accepted: 05/13/2014] [Indexed: 01/06/2023] Open
Abstract
BACKGROUND AND PURPOSE Restless legs syndrome (RLS) is a common sleep-related movement disorder that is frequently associated with psychological disturbances. Personality traits are of considerable importance with respect to coping with chronic illness and disease vulnerability. This study assessed the temperament and character traits of RLS patients using an approach that involves the psychobiological model of personality. METHODS The personality features of 65 newly diagnosed and untreated RLS patients with no neurological or psychiatric diseases and 109 healthy controls were determined using the Temperament and Character Inventory and compared using covariance analyses. The International RLS Study Group Severity Scale was used to assess the severity of the RLS symptoms, and the Beck Depression Inventory was used to assess the presence and severity of depressive symptoms. RESULTS RLS patients scored significantly higher than healthy controls on the temperament dimension of harm avoidance (HA, p=0.02) and significantly lower on self-directedness (SD, p=0.001). No significant difference was observed in terms of the temperament dimension of novelty seeking (p=0.435). HA scores were significantly correlated with the BDI score but not with the RLS severity or duration. CONCLUSIONS High HA and low SD scores are the main characterizing personality features of RLS patients. These personality dimensions may be among the factors predisposing patients to development of the depressive symptoms that are frequently associated with RLS.
Collapse
Affiliation(s)
| | - Sibel Gazioglu
- Department of Neurology, Karadeniz Technical University Medical Faculty, Trabzon, Turkey
| | - Nuray Can Usta
- Department of Neurology, Karadeniz Technical University Medical Faculty, Trabzon, Turkey
| | - Evrim Ozkorumak
- Department of Psychiatry, Karadeniz Technical University Medical Faculty, Trabzon, Turkey
| | - Ahmet Ayar
- Department of Physiology, Karadeniz Technical University Medical Faculty, Trabzon, Turkey
| | - Murat Topbas
- Department of Public Health, Karadeniz Technical University Medical Faculty, Trabzon, Turkey
| | - Cavit Boz
- Department of Neurology, Karadeniz Technical University Medical Faculty, Trabzon, Turkey
| |
Collapse
|
22
|
Baeken C, Bossuyt A, De Raedt R. Dorsal prefrontal cortical serotonin 2A receptor binding indices are differentially related to individual scores on harm avoidance. Psychiatry Res 2014; 221:162-8. [PMID: 24412555 DOI: 10.1016/j.pscychresns.2013.12.005] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2012] [Revised: 11/20/2013] [Accepted: 12/19/2013] [Indexed: 01/15/2023]
Abstract
Although the serotonergic system has been implicated in healthy as well as in pathological emotional states, knowledge about its involvement in personality is limited. Earlier research on this topic suggests that post-synaptic 5-HT2A receptors could be involved in particular in frontal cortical areas. In drug-naïve healthy individuals, we examined the relationship between these 5-HT2A receptors and the temperament dimension harm avoidance (HA) using 123I-5-I-R91150 single photon emission computed tomography (SPECT). HA is a personality feature closely related to stress, anxiety and depression proneness, and it is thought to be mediated by the serotonergic system. We focused on the prefrontal cortices as these regions are frequently implicated in cognitive processes related to a variety of affective disorders. We found a positive relationship between dorsal prefrontal cortical (DPFC) 5-HT2A receptor binding indices (BI) and individual HA scores. Further, our results suggest that those individuals with a tendency to worry or to ruminate are particularly prone to display significantly higher 5-HT2A receptor BI in the left DPFC. Although we only examined psychologically healthy individuals, this relationship suggests a possible vulnerability for affective disorders.
Collapse
Affiliation(s)
- Chris Baeken
- Department of Psychiatry and Medical Psychology, Ghent University, De Pintelaan 185, 9000 Ghent, Belgium; Department of Psychiatry, University Hospital UZBrussel, Brussels, Belgium; Ghent Experimental Psychiatry (GHEP) Lab, Ghent, Belgium.
| | - Axel Bossuyt
- Department of Nuclear Medicine, University Hospital UZBrussel, Brussels, Belgium
| | - Rudi De Raedt
- Department of Experimental Clinical and Health Psychology, Ghent University, Ghent, Belgium
| |
Collapse
|